NewLink Genetics Corp (NASDAQ:NLNK) Expected to Announce Earnings of -$0.29 Per Share

Brokerages expect NewLink Genetics Corp (NASDAQ:NLNK) to report earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for NewLink Genetics’ earnings. NewLink Genetics posted earnings per share of ($0.47) during the same quarter last year, which would indicate a positive year over year growth rate of 38.3%. The company is scheduled to report its next earnings report on Tuesday, July 30th.

On average, analysts expect that NewLink Genetics will report full-year earnings of ($0.10) per share for the current financial year. For the next fiscal year, analysts expect that the company will report earnings of ($1.13) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow NewLink Genetics.

NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.04. NewLink Genetics had a negative net margin of 1,691.08% and a negative return on equity of 38.63%. The company had revenue of $0.11 million during the quarter.

NLNK has been the subject of several research reports. ValuEngine downgraded shares of NewLink Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Robert W. Baird decreased their target price on shares of NewLink Genetics from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, February 28th. Finally, Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Wednesday, March 6th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. NewLink Genetics has an average rating of “Hold” and a consensus price target of $3.75.

NLNK opened at $1.64 on Tuesday. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.07. NewLink Genetics has a 52-week low of $1.28 and a 52-week high of $5.49. The company has a market cap of $57.78 million, a price-to-earnings ratio of -1.14 and a beta of 1.61.

Several hedge funds have recently made changes to their positions in the company. State of Wisconsin Investment Board boosted its stake in shares of NewLink Genetics by 29.8% in the first quarter. State of Wisconsin Investment Board now owns 38,300 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 8,800 shares during the period. Rhumbline Advisers boosted its stake in shares of NewLink Genetics by 41.4% in the fourth quarter. Rhumbline Advisers now owns 40,387 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 11,830 shares during the period. Geode Capital Management LLC boosted its stake in shares of NewLink Genetics by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 497,756 shares of the biotechnology company’s stock valued at $756,000 after purchasing an additional 14,944 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of NewLink Genetics by 31.8% in the first quarter. Parametric Portfolio Associates LLC now owns 69,872 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 16,858 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of NewLink Genetics in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 34.30% of the company’s stock.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Featured Story: What is Call Option Volume?

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.